Rapid growth in the Second Class Vaccine Market TOP5 products account for 90% of the vaccine market

In mid-July 2018, after the problem of rabies vaccine for people with permafrost in Changchun was exposed, the scope of the events became the most in history. However, "Beijing Middle-year under the flu" brush screen, still in many people's mind to leave memories, North of the Yangtze River in China has gradually entered the autumn, and to the influenza virus vaccine and pneumococcal polysaccharide vaccination season, affected by the flu events in early 2018, this autumn and winter vaccination is worthy of attention.
with the promotion of resistance, improving human immunity is imperative, the competent authorities on vaccine regulation and improve public awareness of vaccines has been put on the agenda. Proper understanding of the role of vaccines, the effectiveity of vaccines, the benefits of vaccinations, and even adverse reactions are becoming common sense in health care.the rapid growth of the second-class vaccine market in public hospitals
with the rapid development of the global vaccine market, China's new vaccine products have also been listed. In the past two years, the National Drug Administration has approved Pfizer's 13-price pneumococcal polysaccharide-binding vaccine, and on April 28, 2018, the four-priced human papillomavirus vaccine Jiadashu and GlaxoSmithKline's pyridodic human papillomavirus adsorption vaccine, Giashu 9, were approved in Mercado.
Domestic new vaccine has also developed rapidly, on August 12, 2018, the State Drug Administration approved the Beijing Minhai Biotech's 23-price pneumococcal polysaccharide vaccine, which is a new result of the recombinant Ebola virus disease vaccine registered with Consino Biodevelopment in 2017, the 23-price pneumococcal polysaccharide vaccine of Yuxi Watson Biotechnology, the Institute of Medical Biology of the Chinese Academy of Medical Sciences and the enterovirus type 71 sterilization vaccine of Beijing Science and Technology.
2017, the amount of vaccine drugs used in public hospitals in key cities in China was 163 million yuan, an increase of 8.20% over the previous year, according to Minanet data. The top5 vaccine varieties of great concern are the human rabies vaccine, the bovine pox vaccine, the copper-green prosthetic monocytobacteria, the carcass and the recombined hepatitis B vaccine, accounting for 90% of the vaccine market.
, in Beijing, the nine-priced human papillomavirus vaccine Jiadashu 9 to complete the full vaccination procedures need 3898 yuan, at their own expense, still have to queue up to make an appointment for vaccination. At present, the human papillomavirus vaccine Jiadasso and Pfizer's 13-price pneumococcal polysaccharide-binding vaccine has not yet been counted in the city's public hospital vaccine data.flu vaccine 2017 heat, 2018 Xiaoice river period does not cool down
influenza virus has always threatened humanity, is the source of a variety of secondary diseases, become a serial killer of immunodeficiency. In 2017, consumption of influenza virus lyseveration vaccine in key urban public hospitals increased by 30.68 percent year-on-year, heating up rapidly in the years of ups and downs, with Sanofi accounting for 97.59 percent of the market pattern, Beijing Kexing Bio 0.88 percent, GlaxoSmithKline 0.68 percent and Zhejiang Tianyuan Biopharmaceuser 0.55 percent, according to Minanet data.
Under the direct influence of influenza virus on the respiratory system, secondary pneumococcal infection is the causative factor of meningitis, mycobacteremia and pneumonia, as well as one of the pathogenic factors of sinusitis, otitis middle ear and other common diseases. It is expected that in 2018, under the prospect of free vaccination for the elderly in most cities, sales will not decline, but the number of older people who self-pay to vaccinate imported seedlings may increase, and the four-priced seedlings will once again stimulate consumption.Pneumococcal polysaccharide vaccine heating up
According to the annual report of multinational companies, sales of the three pneumococcal polysaccharide vaccines in 2017 amounted to US$7.151 billion, an increase of 1.53% year-on-year;
2017, sales of pneumococcal polysaccharide vaccines in public hospitals in key cities reached 720,000 yuan, up 178.02% year-on-year, showing a warming trend, according to Mienet data. Among them, Neumofa in Mesa East accounted for 53.01 percent, Chengdu Biotech's Huikang accounted for 42.87 percent, Sanofi Pasteur's Uber 23 accounted for 2.95 percent, and Yuxi Watson Bio accounted for 1.17 percent.
about 1.6 million people worldwide die each year from pneumococcal disease, most of them infants and the elderly. Flu and pneumococcal vaccines for high-risk groups can effectively reduce risk. The U.S. Centers for Disease Control and Prevention recommends a 23-pneumococcal polysaccharide vaccine for people over 65 years of age and 2-64 years of age with immunodeficiency.
, the most commonly used pneumococcal polysaccharide vaccines worldwide are Pfizer's Prevnar13, Mercado's 23-price pneumococcal polysaccharide vaccine Pneumoovax, and GlaxoSmithKline's 10-price pneumococcal vaccine Synflorix. In the Chinese market, Mercado's 23-price pneumococcal polysaccharide vaccine Newmofa, Sanofi's 23-price pneumococcal polysaccharide vaccine Uber 23, Pfizer's Prevnar13 have been approved for the market.
On August 12, 2018, the State Drug Administration approved the 23-price pneumococcal polysaccharide vaccine of Minhai Biotech in Beijing, thus forming a competitive situation for the 23-price pneumococcal polysaccharide vaccine troika of Huiyikang and Yuxi Watson biology of Chengdu Institute of Biological Products.The hepatitis B vaccine market has been down and down
According to the 2015 edition of the Chinese Medical Association's Guidelines for the Prevention and Control of Chronic Hepatitis B, about one-third of the world's population has been infected with hepatitis B virus, of which 240 million people are infected with chronic hepatitis B virus (HBV), and 650,000 die each year from various liver diseases caused by HBV infection. There are 93 million people infected with chronic hepatitis B virus in China, of whom 20 million are chronic hepatitis B patients (CHB), and the annual expenditure on treatment is as high as 30 billion to 50 billion yuan. With the global promotion of hepatitis B vaccination, the efficiency of vaccination in newborn populations is expected to change the carriers and conditions of HBV in a few years' time.
according to World Health Organization data, people who are not infected with the hepatitis B virus, according to the procedures of hepatitis B vaccine, more than 95% of people can obtain HBV lifetime immunity. In theory, the hepatitis B vaccine is a potential variety. In particular, the hepatitis B vaccine was officially included in the national immunization program, led to the development of the domestic hepatitis B vaccine industry.
according to Mienet data, in 2017 the domestic key cities public hospital hepatitis B vaccine sales of 7.42 million yuan, ranking fifth in the second-class vaccine market, overall showed a volatile development trend.
market pattern, Dalian Hanxin accounted for 34.48 percent, GlaxoSmithKline accounted for 32.58 percent, Shenzhen Kantai accounted for 16.76 percent, North China Jintan accounted for 13.94 percent, Beijing North Bio 2.13 percent, Hualan Bio 0.11 percent. Hepatitis B vaccine has been included in the scope of immunization, the implementation of the second type of vaccine and a class of vaccines, adults to get hepatitis B vaccine still need to be included in the self-cost system, and hepatitis A and B vaccine, recombined hepatitis E vaccine belongs to the second category of vaccines, is one of the important varieties of the second type of vaccine. With the arrival of China's baby boom, the number of newborn babies, vaccination rate will be increased year by year, and the self-cost hepatitis B vaccine market can not be underestimated, thus promoting the growth of the hepatitis B vaccine market. rabies vaccine remains high
for nearly 10 years, public hospitals in key cities have been the first to use rabies vaccine. According to Minetrain data, the amount of rabies vaccine used in public hospitals in key cities in 2017 was 70.72 million yuan, an increase of 43.04 percent over the previous year.
TOP3 manufacturers are Liaoning Chengda Bio accounted for 65.20%, Chengdu Kanghua accounted for 18.27%, Guangzhou No cheng Bio accounted for 11.63%, the above three accounted for more than 95% of the proportion, other manufacturers accounted for 4.9%. Sanofi's rabies vaccine was withdrawn from the domestic market in 2009 because it did not comply with the 2010 edition of the pharmacopeia, with a smaller share of the rebids in Kairong Bellin, India.
characteristics of rabies vaccinations differ from those of other vaccines and are mainly used for emergency prevention. Domestic public hospital rabies vaccine market data is only the tip of the iceberg, the domestic market is about 10 billion yuan, especially the urban secondary hospital health department, health and epidemic prevention stations, county-level hospitals and rural health hospitals occupy an important proportion. (Mi Net)